Paris, September 4, 2025 — Leads & Copy — PulseSight Therapeutics CSO, Thierry Bordet, Ph.D., presented new data on iron dysregulation and ferroptosis in age-related macular degeneration (AMD) at the 25th EURETINA Congress in Paris.
The study, conducted with Inserm and Cochin Hospital, confirmed elevated iron and increased transferrin saturation in aqueous humors of AMD patients, reinforcing the therapeutic relevance of iron modulation in geographic atrophy (GA).
Dr. Bordet also presented topline data from a study on the role of transferrin in preventing ferroptosis, an iron-dependent cell death contributing to AMD pathology. Full results have been submitted for peer-reviewed publication.
These findings support the development of PulseSight’s lead therapy, PST-611, a first-in-class non-viral vectorized therapy encoding transferrin to restore iron balance in dry AMD/ GA. PST-611 entered a phase I clinical trial earlier this year.
PST-611 encodes human transferrin, regulating iron homeostasis and addressing key pathological mechanisms in dry AMD/GA, requiring re-treatment every four to six months. It entered a Phase I clinical trial (PST-611-CT1) in France in 2025.
AMD affects 200 million people worldwide and is the leading cause of central vision loss in the elderly. The AMD market is estimated to reach $27.5 Billion by 2031.
Media contact: Sue Charles, Charles Consultants, T: +44 (0)7968 726585, E: sue@charles-consultants.com
Source: PulseSight Therapeutics
